BCIQ Profiles

Company Profile ReportTarget Profile Report
0504 9 AM PT Vivace
BioCentury & Getty Images

Targets & Mechanisms

With an eye toward M&A, Vivace aims to establish POC for emerging solid tumor target TEAD

Compound could deliver first clinical signal for therapies against Hippo pathway

Vivace’s TEAD inhibitor could deliver the first clinical signal for therapies against the Hippo pathway.

May 4, 2021 | 7:40 PM GMT

Vivace believes

Read the full 595 word article

How to gain access

Continue reading with a
two-week free trial.